AHNAK2 is a potential prognostic biomarker in patients with PDAC

Di Lu; Junxiong Wang; Xiaoyan Shi; Bing Yue; Jianyu Hao

doi:10.18632/oncotarget.15990

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

AHNAK2 is a potential prognostic biomarker in patients with PDAC

Di Lu, Junxiong Wang, Xiaoyan Shi, Bing Yue and Jianyu Hao _

PDF | HTML | How to cite

Oncotarget. 2017; 8:31775-31784. https://doi.org/10.18632/oncotarget.15990

Metrics: PDF 2308 views | HTML 4004 views | ?

Abstract

Di Lu1, Junxiong Wang1, Xiaoyan Shi2, Bing Yue2 and Jianyu Hao1

1Department of Gastroenterology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China

2Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Correspondence to:

Jianyu Hao, email: [email protected]

Keywords: AHNAK2, pancreatic ductal adenocarcinoma, overall survival, prognostic factor, nomogram

Received: October 09, 2016 Accepted: February 21, 2017 Published: March 07, 2017

ABSTRACT

Background: AHNAK nucleoprotein 2 (AHNAK2) belongs to the AHNAK protein family. The studies of AHNAK2 are limited. A recent study reported that AHNAK2 might be a biomarker for pancreatic ductal adenocarcinoma (PDAC); however, tissue-based experiments have not been conducted. The aim of this study was to determine the tissue expression of AHNAK2 and to find the correlation between AHNAK2 and overall survival rate in PDAC.

Results: AHNAK2 is highly expressed in PDAC (n=79) compared with adjacent normal tissues (n=64, P<0.001). Overexpression of AHNAK2 showed a significant relationship with a lower overall survival rate (P=0.033) in PDAC patients. The predictive value of increased expression of AHNAK2 remains relevant in patients with AJCC grade above II (n=43, P=0.006) or lymph node metastasis (n=32, P=0.004). Cox regression analysis showed that AHNAK2 expression (P=0.003) and pathology grade (P<0.001) are independent prognostic factors for PDAC. The nomogram model was performed to predict the 1- and 3-year survival rates based on Cox regression. The C-index was 0.61. The calibration curves were also made to show the association between the observed and predicted probability of the overall survival rates.

Materials and Methods: AHNAK2 expression was performed in tissue microarrays by immunohistochemistry. The overall survival rate analysis was performed using the Kaplan–Meier method, Cox proportional hazards regression, and a nomogram model.

Conclusions: AHNAK2 is overexpressed in PDAC tissues and is an independent prognostic factor in patients with PDAC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15990

Publication Alerts

Research Papers:

AHNAK2 is a potential prognostic biomarker in patients with PDAC

Abstract